Dr. Reddy's Lab regains worldwide rights to DFA-02

01 Oct 2018 Evaluate

Dr. Reddy’s Laboratories along with its subsidiaries has terminated the license granted to Armis Biopharma (formerly known as CHO Bioscience) for its investigational antibacterial product, DFA-02, for the prophylaxis of surgical site infections (SSIs). As a result of the termination, the company has regained worldwide rights to DFA-02, and is currently evaluating its options to take the program forward.

DFA-02 is a combination, broad spectrum antibacterial in situ gel which is being investigated for the prophylaxis of SSIs as an adjunct to conventional preoperative antibiotic prophylaxis. DFA-02 has been studied in several phase 1 and 2 clinical studies, and has demonstrated clinical efficacy in several key segments of patients who were at high risk for SSIs.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1175.55 -10.90 (-0.92%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×